Coffee Drinkers Show 43% Lower Risk of Oral and Throat Cancers, Meta-Analysis Finds

For billions of people, the day does not properly begin until the first cup of coffee has been poured. Now a large-scale synthesis of the scientific literature suggests that this daily ritual may be doing far more than sharpening attention and lifting mood. A systematic review and meta-analysis published in BMC Cancer has found that people who drink more coffee have a substantially lower risk of developing oral and pharyngeal cancers, a group of malignancies that together account for hundreds of thousands of new cases and deaths worldwide every year. The study, led by Yi Duan of the Affiliated Hospital of Beihua University together with colleagues from hospitals across China, pooled data from twenty observational studies to arrive at one of the most precise estimates yet of the relationship between coffee intake and cancers of the mouth and throat.

The headline figure is striking. Compared with lower or no consumption, higher coffee consumption was associated with a pooled relative risk of 0.57, with a 95 percent confidence interval of 0.49 to 0.66. In practical terms, that corresponds to a 43 percent reduction in the risk of oral and pharyngeal cancer among heavier coffee drinkers, and the confidence interval sits entirely below 1.0, meaning the association is statistically significant by conventional standards. In epidemiology, where effect sizes for dietary factors are often modest and easily eroded by confounding, a reduction of this magnitude is unusual and demands attention. It places coffee in the same conversation as other dietary factors that have been linked to head and neck cancer risk, but with an inverse rather than harmful direction.

The methodology behind the estimate reflects the current gold standard for evidence synthesis. The researchers systematically searched PubMed/MEDLINE, Scopus, Web of Science, the Cochrane Library, and Google Scholar from database inception through March 2026, casting a wide net for observational studies that assessed coffee consumption and the risk of oral or pharyngeal cancer. After applying their inclusion criteria, they retained twenty studies. To combine the results, they used a random-effects inverse-variance model with DerSimonian and Laird estimation, a technique that does not assume all studies share a single true effect size but instead models the variability between them. This choice matters, because dietary exposure measurements, population characteristics, and cancer definitions inevitably differ from one study to the next, and a fixed-effect model would have understated that uncertainty.

That variability was real but manageable. The analysis observed moderate heterogeneity across the included studies, quantified by an I-squared statistic of 46.0 percent. Heterogeneity describes how much of the spread in study results reflects genuine differences rather than chance; values below roughly 50 percent are generally considered moderate. In this case, the moderate level suggests that while the studies did not produce identical estimates, they told a broadly consistent story. Crucially, the inverse association between coffee and cancer risk held up when the researchers split the data by geographical region, by study design, and by cancer site, meaning the protective signal was not confined to one continent, one type of study, or one anatomical location within the oral cavity and pharynx.

The authors also took deliberate steps to rule out two of the most common artifacts that plague meta-analyses. Publication bias, the tendency for small studies with dramatic findings to be published more readily than null results, was assessed with Egger’s test, which examines whether smaller studies systematically report larger effects. The result was reassuring: no significant small-study effects were detected, with a p-value of 0.166. Sensitivity analyses, in which individual studies are removed or analytical choices are varied to see whether the pooled estimate wobbles, confirmed the stability of the results. Together, these checks strengthen the case that the observed association is not a statistical mirage created by selective reporting or by the outsized influence of a few outliers.

Why might coffee protect the tissues of the mouth and throat? The biological plausibility rests on well-characterized chemistry. Coffee is one of the richest dietary sources of polyphenols and other bioactive compounds, including chlorogenic acids, caffeic acid, and melanoidins formed during roasting. These molecules exhibit antioxidant activity, neutralizing the reactive oxygen species that can damage DNA in epithelial cells lining the oral cavity and pharynx. They also display anti-inflammatory properties, dampening the chronic inflammation that is increasingly recognized as a driver of carcinogenesis, and antiproliferative effects, slowing the uncontrolled cell division that defines cancer. Some coffee compounds have been shown in laboratory studies to influence phase II detoxification enzymes, enhance DNA repair, and induce apoptosis in pre-malignant cells, offering several mechanistic routes by which a daily beverage could plausibly influence tumor initiation and progression in exposed tissues.

The population-level stakes are considerable. Oral and pharyngeal cancers are major contributors to global cancer-related morbidity and mortality, and their burden is concentrated in regions where tobacco smoking, alcohol consumption, and chewing-related exposures, such as betel quid, are prevalent. Because these cancers are strongly linked to modifiable behaviors, prevention strategies have traditionally focused on tobacco and alcohol control, and rightly so. But the finding that a widely consumed, inexpensive, and socially embedded beverage is associated with markedly lower risk suggests a potential complementary avenue for prevention, particularly in high-burden regions where coffee drinking is culturally established. Unlike novel chemopreventive drugs, coffee requires no new infrastructure, no prescription, and no behavioral revolution.

Yet the researchers are careful, and rightly so, about the limits of what their study can claim. All twenty included studies were observational, meaning they measured what people drank and tracked who developed cancer, rather than randomly assigning coffee in a controlled trial. Observational designs are vulnerable to confounding: coffee drinkers differ from non-drinkers in many ways, including smoking habits, alcohol intake, diet, socioeconomic status, and access to healthcare, and even sophisticated statistical adjustment cannot fully eliminate these differences. Reverse causation is another concern, since early symptoms of disease can change dietary habits before a diagnosis is made. The authors explicitly state that causal inference is limited by the observational nature of the included studies and by variability in how coffee exposure was assessed across studies, which ranged from broad categories to detailed cup-per-day measurements.

That caution should shape how the findings are communicated and consumed. A 43 percent lower risk among coffee drinkers does not mean that drinking coffee will prevent cancer in any individual, nor does it license ignoring the dominant risk factors. Tobacco and alcohol remain overwhelmingly stronger determinants of oral and pharyngeal cancer risk, and no amount of coffee offsets the carcinogenic assault of smoking or heavy drinking. What the meta-analysis provides is a robust, internally consistent observational signal, one that now warrants deeper investigation through cohort studies with detailed exposure assessment, biomarker-based mechanistic research, and, ultimately, trials or natural experiments that can probe causality more directly. It also raises practical questions worth studying, such as whether temperature, preparation method, caffeine content, or additive use modifies the association.

For now, the study adds coffee to a growing list of dietary components, alongside fruits, vegetables, and other polyphenol-rich foods, that are associated with reduced head and neck cancer risk in observational data. The convergence of a large pooled effect, consistency across regions and designs, absence of publication bias, and credible biological mechanisms makes this one of the more compelling dietary-cancer associations reported in recent years. Whether that association survives the scrutiny of randomized evidence remains to be seen, but for the world’s coffee drinkers, the latest science offers an unusually reassuring verdict: the beverage that starts the morning may also, quietly, be defending the tissues it passes on the way down.

Subject of Research: The association between coffee consumption and the risk of oral and pharyngeal cancers

Article Title: Association between coffee consumption and oral and pharyngeal cancers: a systematic review and meta-analysis

Article References: Duan, Y., Guo, M., Mou, T., & Zeng, C. (2026). Association between coffee consumption and oral and pharyngeal cancers: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-17132-6

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17132-6

Keywords: coffee, oral cancer, pharyngeal cancer, meta-analysis, systematic review, cancer prevention, chemoprevention, head and neck cancer, polyphenols, antioxidants, epidemiology, BMC Cancer